CClinicalTrials.gg
RecruitingNCT06012461Updated Sep 5, 2023

Closed-loop DBS in Parkinson's Disease

An interventional study of Closed-loop DBS stimulation for 24 hours and Open-loop DBS stimulation for 24 hours in Parkinson Disease, sponsored by Tsinghua University. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-09-05.

Sponsored by Tsinghua University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 9 months ago, but the record still lists the study as recruiting.
  • Started Jun 2023; still recruiting 3 years 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Closed-loop DBS is an emerging neuromodulation pattern in Parkinson's disease with dyanmic adjustment of stimulation parameters to patients' disease fluctuations and state of activity. The purpose of this study is to verify the long-term safety and effectiveness of closed-loop DBS. Through comparing with open-loop DBS, the study also determine whether closed-loop DBS is more effective than conventional open-loop DBS on PD treatment.

02

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • Parkinson Disease
  • Deep Brain Stimulation
  • Closed-loop DBS
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's planned enrollment of 10 is below the median of 40 across 3,294 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Tsinghua University is the lead sponsor of 24 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Diagnosis of primary Parkinson's disease: Diagnosis of primary Parkinson's disease should meet the diagnostic criteria outlined in the "Diagnosis Standards for Parkinson's Disease in China" published in 2016 or the diagnostic criteria for primary Parkinson's disease by the International Parkinson and Movement Disorder Society (MDS) published in 2015.
  2. Good response to levodopa combination therapy.
  3. Significant reduction in drug efficacy or significant impact on the patient's quality of life due to prominent motor complications.
  4. Intolerable adverse reactions to medication affecting its efficacy.
  5. Presence of uncontrollable tremors despite medication.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have undergone pallidotomy or other brain surgeries.
  2. Patients with secondary Parkinson syndromes or Parkinson plus syndromes.
  3. Patients with concurrent central nervous system and peripheral nervous system diseases.
  4. Patients with severe systemic diseases, unstable vital signs, or those who cannot tolerate clinical assessments.
  5. Patients with severe psychiatric disorders.
  6. Patients who are unable to provide informed consent due to cognitive or communication impairments or those who refuse to sign the informed consent form.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Bilateral STN DBS Modulation

    Participants will be implanted with bilateral STN DBS using PINS 106RS system. DBS stimulation will be initiated one month post surgery. Follow-up visits will be conducted 1/3/6/9/12/15 months post surgery with clinical evaluation, STN LFP recording and resting state functional MRI testing. During the 6-15 month's visit, short-term closed-loop DBS modulation (from 24hours to 72hours ) will be conducted to test the safety and efficacy of closed-loop DBS therapy.

    Other: Closed-loop DBS stimulation for 24 hours · Other: Open-loop DBS stimulation for 24 hours · Other: Closed-loop DBS stimulation for 72 hours · Other: Open-loop DBS stimulation for 72 hours

Interventions

  • OtherClosed-loop DBS stimulation for 24 hours

    Continuous closed-loop modulation for 24 hours

  • OtherOpen-loop DBS stimulation for 24 hours

    Continuous open-loop modulation for 24 hours

  • OtherClosed-loop DBS stimulation for 72 hours

    Continuous closed-loop modulation for 72 hours

  • OtherOpen-loop DBS stimulation for 72 hours

    Continuous open-loop modulation for 72 hours

06

What researchers measure

Primary outcomes

  1. Movement disorders evaluation

    Using MDS-UPDRS III rating scale (0-132, the higher score means a worse outcome) and Rush dyskinesia rating scale (0-12, the higher score means a worse outcome) combined with IMU to evaluate the motor function improvement under both closed-loop DBS and open-loop DBS condition

    Time frame: 1-3 days

  2. Sleep Structure Evaluation

    Using polysomnography evaluation (sleep efficiency,N1/N2/N3/REM/Wake after sleep onset duration and percentage,arousal index) and subjuective sleep quality rating scale to evaluate the sleep improvement under both closed-loop DBS and open-loop DBS condition

    Time frame: 1-3 nights

  3. Diary Outcomes in Parkinson's Disease

    Using SCOPA-DC (0-87, the higher score means a worse outcome) to evaluate the diary outcomes under both closed-loop DBS and open-loop DBS condition

    Time frame: 1-3days

Secondary outcomes

  1. Safety (Stimulation-related AEs) and Subjective Satisfactory

    Number of modulation related Adverse Events or abnormal vital signs.

    Time frame: 1-3days

  2. Total Electrical Energy Delivered to patients

    To evaluate the energy changes in closed-loop DBS and open-loop DBS modualtion

    Time frame: 1-3days

Other outcomes

  1. Neurophysiological changes of STN-LFP in daytime and sleep

    Changes of the power and entropy features of delta, theta, alpha, beta and gamma oscillations

    Time frame: at 3,6,9,12,15 months compared to baseline

  2. Functional connectivity changes during long-term DBS modulation

    Changes of subcortical and cortical functional connectivity

    Time frame: at 3,6,9,12,15 months compared to baseline

07

Study locations

1 of 1 sites recruiting
  • National Engineering Research Center of Neuromodulation
    Beijing, Beijing 100084, China
    • Huiling Yu, M.D. · Contact · hellokittylene@163.com · 86-010-62794952
    • Luming Li, Ph.D. · Principal investigator
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06012461
Lead sponsor
Tsinghua University
Collaborators
National Engineering Research Center of Neuromodulation, Tsinghua University, Beijing Tiantan Hospital, Peking Union Medical College Hospital, Beijing Pins Medical Co., Ltd
Responsible party
Luming Li (Professor, Tsinghua University) — Principal investigator
First posted
Aug 25, 2023
Start date
Jun 30, 2023
Primary completion
Dec 30, 2024 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Sep 5, 2023

Study contacts

Weizhi Pan, B.S.
Contact
neln@mail.tsinghua.edu.cn
+86-010-62796172

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion